ResMed Inc. (RMD)
ResMed Inc. (RMD) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript
ResMed Inc. (RMD) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript
ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Hidden 401(k) Tax Bomb That Hits a $1.3 Million Saver With $19,800 in Their First RMD Year
Picture a single 73-year-old retiree sitting on $1.3 million in a traditional 401(k), drawing $36,000 a year in Social Security, and feeling reasonably set for retirement.
The In Plan Roth 401(k) Conversion That Saves a $400,000 Earner $58,000 in Future RMD Taxes
Picture a 55-year-old earning $400,000 with $1.5 million in a traditional 401(k).
Is the Options Market Predicting a Spike in ResMed Stock?
Investors need to pay close attention to RMD stock based on the movements in the options market lately.
Here's Why ResMed (RMD) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
RMD Stock Down Despite Q3 Earnings & Revenue Beat, Margins Rise
Resmed beats Q3 earnings and revenue estimates with strong margin gains, yet shares slip post earnings despite growth across key segments.
ResMed (RMD) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Wall Street's Insights Into Key Metrics Ahead of ResMed (RMD) Q3 Earnings
Besides Wall Street's top-and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth
ResMed (RMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Resmed's Q3 Earnings on Deck: What's in Store for the Stock?
RMD gears up for fiscal Q3 earnings with steady estimates, rising demand in sleep devices and AI-driven digital health tools poised to shape results.
Why ResMed (RMD) is Poised to Beat Earnings Estimates Again
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
